PolyPid (PYPD) Q3 2024 earnings summary

Executive summary

• SHIELD II pivotal trial for D-PLEX 100 accelerated enrollment, with over 550 patients enrolled across about 60 global centers; all planned sites are open and recruiting, with enrollment completion expected December 2024 and top-line results anticipated in Q1 2025.

• SHIELD II is a de-risked phase III trial, leveraging positive, statistically significant data from the prior SHIELD I study, which was published in a leading surgical journal and showed significant efficacy in high-risk subgroups.

• Ongoing discussions with potential strategic partners for U.S. commercialization, with global market opportunities identified in Europe, South America, China, India, and Japan.

Financial highlights

• Cash and cash equivalents plus short-term deposits totaled $9.5 million as of September 30, 2024, up from $5.3 million at year-end 2023.

• Net loss for Q3 2024 was $7.8 million ($1.22/share), compared to $5.6 million ($3.40/share) in Q3 2023.

• Research and development expenses rose to $6 million in Q3 2024 from $3.8 million in Q3 2023, driven by increased SHIELD II enrollment.

• Nine-month 2024 net loss was $20.5 million ($3.82/share) versus $17.5 million ($13.59/share) in the same period 2023.

• G&A and marketing/business development expenses were $246,000 and $1.2 million, with year-over-year decreases due to cost savings.

Outlook and guidance

• Interim analysis outcome for SHIELD II is expected later this quarter, with enrollment completion by December 2024 and top-line results in Q1 2025; NDA submission targeted for 2026, assuming timely trial completion and breakthrough therapy designation.

• Current cash is expected to fund operations into Q1 2025; runway could extend into 2026 if all warrants from January and August 2024 PIPE financings are exercised.